User menu

Calcium channel blockers in cardiovascular pharmacotherapy

Bibliographic reference Godfraind, Theophile. Calcium channel blockers in cardiovascular pharmacotherapy. In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 19, no. 6, p. 501-515 (2014)
Permanent URL
  1. Schaper WK, J Pharmacol Exp Ther, 152, 265 (1966)
  2. Haas H, Arzneim-Forsch, 12, 461 (1964)
  3. Vater W, Arzneimittelforschung, 22, 1 (1972)
  4. Sato M, Arzneimittelforschung, 21, 1338 (1971)
  6. Godfraind T, Arch Int Pharmacodyn Ther, 196, 35 (1972)
  7. Godfraind T, Br J Pharmacol, 35, P354 (1969)
  8. Godfraind T, Arch Int Pharmacodyn Ther, 172, 235 (1968)
  9. GODFRAIND T., KABA A., Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle, 10.1111/j.1476-5381.1969.tb08010.x
  10. Godfraind T, Thérapie, 23, 1209 (1968)
  11. Godfraind T, Pharmacol Rev, 38, 321 (1986)
  12. Fleckenstein A, Circ Res, 52, I3 (1983)
  13. Godfraind T, Acta Pharmacol Toxicol (Copenh), 58, 5 (1986)
  14. Godfraind Théophile, Calcium Channel Blockers, ISBN:9783034895996, 10.1007/978-3-0348-7859-3
  15. Evans D. H. L., Schild H. O., Thesleff S., Effects of drugs on depolarized plain muscle, 10.1113/jphysiol.1958.sp006072
  16. EDMAN K. A. P., SCHILD H. O., Interaction of Acetylcholine, Calcium and Depolarization in the Contraction of Smooth Muscle, 10.1038/190350b0
  17. Edman K. A. P., Schild H. O., Calcium and the stimulant and inhibitory effects of adrenaline in depolarized smooth muscle, 10.1113/jphysiol.1963.sp007265
  18. Edman K. A. P., Schild H. O., The need for calcium in the contractile responses induced by acetylcholine and potassium in the rat uterus, 10.1113/jphysiol.1962.sp006897
  19. Wibo M., DeRoth L., Godfraind T., Pharmacologic relevance of dihydropyridine binding sites in membranes from rat aorta: kinetic and equilibrium studies, 10.1161/01.res.62.1.91
  20. Godfraind T., Wibo M., Subcellular localization of [3H]-nitrendipine binding sites in guinea-pig ileal smooth muscle, 10.1111/j.1476-5381.1985.tb08866.x
  21. Grover AK, J Biol Chem, 259, 2223 (1984)
  22. Triggle David J., The pharmacology of ion channels: with particular reference to voltage-gated Ca2+ channels, 10.1016/s0014-2999(99)00329-5
  23. Triggle David J., Calcium channel antagonists: Clinical uses—Past, present and future, 10.1016/j.bcp.2007.01.016
  24. Nowycky Martha C., Fox Aaron P., Tsien Richard W., Three types of neuronal calcium channel with different calcium agonist sensitivity, 10.1038/316440a0
  25. Ertel Eric A., Campbell Kevin P., Harpold Michael M., Hofmann Franz, Mori Yasuo, Perez-Reyes Edward, Schwartz Arnold, Snutch Terry P., Tanabe Tsutomu, Birnbaumer Lutz, Tsien Richard W., Catterall William A., Nomenclature of Voltage-Gated Calcium Channels, 10.1016/s0896-6273(00)81057-0
  26. Perez-Reyes E., Van Deusen A. L., Vitko I., Molecular Pharmacology of Human Cav3.2 T-Type Ca2+ Channels: Block by Antihypertensives, Antiarrhythmics, and Their Analogs, 10.1124/jpet.108.145672
  27. Godfraind T., Calcium antagonists and vasodilation, 10.1016/0163-7258(94)90033-7
  28. Godfraind T., Morel N., Wibo M., Tissue specificity of dihydropyridine-type calcium antagonists in human isolated tissues, 10.1016/0165-6147(88)90241-6
  29. Godfraind T, J Pharmacol Exp Ther, 230, 514 (1984)
  30. Sun J, J Pharmacol Exp Ther, 274, 419 (1995)
  31. Godfraind T., Salomone S., Dessy C., Verhelst B., Dion R., Schoevaerts J. C., Selectivity Scale of Calcium Antagonists in the Human Cardiovascular System Based on In Vitro Studies : , 10.1097/00005344-199206205-00006
  32. Opie Lionel H, Yusuf Salim, Kübler Wolfgang, Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: A critical analysis based on 100 studies, 10.1053/pcad.2000.7010
  33. Leonetti G, J Cardiovasc Pharmacol, 4, S319 (1982)
  34. Godfraind T., Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis, 10.1098/rstb.2005.1774
  35. Napoli C., Salomone S., Godfraind T., Palinski W., Capuzzi D. M., Palumbo G., D'Armiento F. P., Donzelli R., de Nigris F., Capizzi R. L., Mancini M., Gonnella J. S., Bianchi A., Chan P. H., 1,4-Dihydropyridine Calcium Channel Blockers Inhibit Plasma and LDL Oxidation and Formation of Oxidation-Specific Epitopes in the Arterial Wall and Prolong Survival in Stroke-Prone Spontaneously Hypertensive Rats   Editorial Comment, 10.1161/01.str.30.9.1907
  36. Kyselovic J., Calcium Channel Blocker Inhibits Western-Type Diet-Evoked Atherosclerosis Development in ApoE-Deficient Mice, 10.1124/jpet.105.089847
  37. Krenek P., Salomone S., Kyselovic J., Wibo M., Morel N., Godfraind T., Lacidipine Prevents Endothelial Dysfunction in Salt-Loaded Stroke-Prone Hypertensive Rats, 10.1161/01.hyp.37.4.1124
  38. Massart P.-E., Donckier J., Kyselovic J., Godfraind T., Heyndrickx G. R., Wibo M., Carvedilol and Lacidipine Prevent Cardiac Hypertrophy and Endothelin-1 Gene Overexpression After Aortic Banding, 10.1161/01.hyp.34.6.1197
  39. Godfraind Théophile, Mennig Damien, Bravo Guadalupe, Chalant Charles, Jaumin Pierre, Inhibition by amlodipine of activity evoked in isolated human coronary arteries by endothelin, prostaglandin F2α and depolarization, 10.1016/0002-9149(89)90961-2
  40. Feron Olivier, Salomone Salvatore, Godfraind Théophile, Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats, 10.1111/j.1476-5381.1996.tb15451.x
  41. Feron Olivier, Salomone Salvatore, Godfraind Theophile, Blood Pressure-Independent Inhibition by Lacidipine of Endothelin-1-Related Cardiac Hypertrophy in Salt-Loaded, Stroke-Prone Spontaneously Hypertensive Rats : , 10.1097/00005344-199506263-00135
  42. Krippeit-Drews P., Morel N., Godfraind T., Effect of Nitric Oxide on Membrane Potential and Contraction of Rat Aorta : , 10.1097/00005344-199204002-00022
  43. BATOVA S, DEWEVER J, GODFRAIND T, BALLIGAND J, DESSY C, FERON O, The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells, 10.1016/j.cardiores.2006.04.013
  44. Salomone Salvatore, Silva Claudia L. M., Morel Nicole, Godfraind Th�ophile, Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery, 10.1007/bf00168443
  45. Godfraind Th�ophile, Salomone Salvatore, Calcium antagonists and endothelial function: Focus on nitric oxide and endothelin, 10.1007/bf00051108
  46. Kyselovic Jan, Krenek Peter, Wibo Maurice, Godfraind Théophile, Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats, 10.1038/sj.bjp.0704398
  47. Balligand J.-L., Godfraind T., Amlodipine and Stroke Prevention, 10.1161/hypertensionaha.107.096610
  48. Furberg C. D., Psaty B. M., Meyer J. V., Nifedipine : Dose-Related Increase in Mortality in Patients With Coronary Heart Disease, 10.1161/01.cir.92.5.1326
  49. Opie Lionel H, Schall Robert, Evidence-based evaluation of calcium channel blockers for hypertension, 10.1016/s0735-1097(01)01728-4
  50. Opie L. H., Messerli F. H., Nifedipine and Mortality : Grave Defects in the Dossier, 10.1161/01.cir.92.5.1068
  51. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 10.1001/jama.288.23.2981
  52. Chrysant S.G., The ALLHAT study: results and clinical implications, 10.1093/qjmed/hcg123
  53. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 10.1001/jama.288.23.2981
  54. Leenen F. H.H., Nwachuku C. E., Black H. R., Cushman W. C., Davis B. R., Simpson L. M., Alderman M. H., Atlas S. A., Basile J. N., Cuyjet A. B., Dart R., Felicetta J. V., Grimm R. H., Haywood L. J., Jafri S. Z.A., Proschan M. A., Thadani U., Whelton P. K., Wright J. T., , Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, 10.1161/
  55. Poole-Wilson Philip A, Lubsen Jacobus, Kirwan Bridget-Anne, van Dalen Fred J, Wagener Gilbert, Danchin Nicolas, Just Hanjörg, Fox Keith AA, Pocock Stuart J, Clayton Tim C, Motro Michael, Parker John D, Bourassa Martial G, Dart Anthony M, Hildebrandt Per, Hjalmarson Åke, Kragten Johannes A, Molhoek G Peter, Otterstad Jan-Erik, Seabra-Gomes Ricardo, Soler-Soler Jordi, Weber Simon, Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial, 10.1016/s0140-6736(04)16980-8
  56. James Paul A., Oparil Suzanne, Carter Barry L., Cushman William C., Dennison-Himmelfarb Cheryl, Handler Joel, Lackland Daniel T., LeFevre Michael L., MacKenzie Thomas D., Ogedegbe Olugbenga, Smith Sidney C., Svetkey Laura P., Taler Sandra J., Townsend Raymond R., Wright Jackson T., Narva Andrew S., Ortiz Eduardo, 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults : Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8), 10.1001/jama.2013.284427
  57. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., , Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 10.1161/01.hyp.0000107251.49515.c2
  58. Go AS, Hypertension, 63, 1230 (2014)
  59. McDonagh MS, Drug Class Reviews (2005)
  60. Ryuzaki Munekazu, Nakamoto Hidetomo, Nishida Eiichi, Sone Masayoshi, Nakajima Sadao, Yoshimoto Mitsuo, Suzuki Yuka, Itagaki Kaori, Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial) : , 10.1097/hjh.0b013e3282ef7adc
  61. Godfraind Théophile, Eglème Cécile, Finet Michel, Jaumin Pierre, The Actions of Nifedipine and Nisoldipine on the Contractile Activity of Human Coronary Arteries and Human Cardiac Tissuein Vitro, 10.1111/j.1600-0773.1987.tb01779.x
  62. Pfisterer Matthias E, Zellweger Michael J, Gersh Bernard J, Management of stable coronary artery disease, 10.1016/s0140-6736(10)60168-7
  63. Opie Lionel H, First line drugs in chronic stable effort angina—the case for newer, longer-acting calcium channel blocking agents, 10.1016/s0735-1097(00)00946-3
  64. Fihn S. D., Gardin J. M., Abrams J., Berra K., Blankenship J. C., Dallas A. P., Douglas P. S., Foody J. M., Gerber T. C., Hinderliter A. L., King S. B., Kligfield P. D., Krumholz H. M., Kwong R. Y. K., Lim M. J., Linderbaum J. A., Mack M. J., Munger M. A., Prager R. L., Sabik J. F., Shaw L. J., Sikkema J. D., Smith C. R., Smith S. C., Spertus J. A., Williams S. V., Anderson J. L., 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons, 10.1161/cir.0b013e318277d6a0
  65. Frishman William H., β-Adrenergic Blockade in Cardiovascular Disease, 10.1177/1074248413484986
  66. Dahlöf Björn, Sever Peter S, Poulter Neil R, Wedel Hans, Beevers D Gareth, Caulfield Mark, Collins Rory, Kjeldsen Sverre E, Kristinsson Arni, McInnes Gordon T, Mehlsen Jesper, Nieminen Markku, O'Brien Eoin, Östergren Jan, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial, 10.1016/s0140-6736(05)67185-1
  67. Zanchetti A., Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial, 10.1161/01.cir.0000039288.86470.dd
  68. Schamroth L., Immediate effects of intravenous verapamil on atrial fibrillation, 10.1093/cvr/5.4.419
  69. SINGH B. N., VAUGHAN WILLIAMS E. M., A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function, 10.1093/cvr/6.2.109
  70. NADEMANEE KOONLAWEE, SINGH BRAMAH N., Control of Cardiac Arrhythmias by Calcium Antagonism, 10.1111/j.1749-6632.1988.tb33397.x
  71. Schamroth L, Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders (1983)
  72. , Camm A. J., Kirchhof P., Lip G. Y. H., Schotten U., Savelieva I., Ernst S., Van Gelder I. C., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., De Caterina R., De Sutter J., Goette A., Gorenek B., Heldal M., Hohloser S. H., Kolh P., Le Heuzey J.-Y., Ponikowski P., Rutten F. H., Vahanian A., Auricchio A., Bax J., Ceconi C., Dean V., Filippatos G., Funck-Brentano C., Hobbs R., Kearney P., McDonagh T., Popescu B. A., Reiner Z., Sechtem U., Sirnes P. A., Tendera M., Vardas P. E., Widimsky P., Vardas P. E., Agladze V., Aliot E., Balabanski T., Blomstrom-Lundqvist C., Capucci A., Crijns H., Dahlof B., Folliguet T., Glikson M., Goethals M., Gulba D. C., Ho S. Y., Klautz R. J. M., Kose S., McMurray J., Perrone Filardi P., Raatikainen P., Salvador M. J., Schalij M. J., Shpektor A., Sousa J., Stepinska J., Uuetoa H., Zamorano J. L., Zupan I., , , , , Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), 10.1093/eurheartj/ehq278
  73. De Simone A, VErapamil Plus Antiarrhythmic drugs Reduce Atrial Fibrillation recurrences after an electrical cardioversion (VEPARAF Study), 10.1016/s0195-668x(03)00311-7
  74. Bühler F. R., Bolli P., Kiowski W., Müller F. B., Erne P., Calcium Antagonists for Identification of Mechanisms and Treatment in Patients with Essential Hypertension, Bayer-Symposium (1985) ISBN:9783642705014 p.445-457, 10.1007/978-3-642-70499-4_29
  75. Morel Nicole, Godfraind Theophile, Selective Interaction of the Calcium Antagonist Amlodipine with Calcium Channels in Arteries of Spontaneously Hypertensive Rats : , 10.1097/00005344-199410000-00002
  76. Zanchetti A, Acta Physiol Scand Suppl, 571, 69 (1988)
  77. Zanchetti Alberto, The renin-angiotensin system and the heart, 10.1016/0002-9343(88)90198-2
  78. Devereux R. B., Palmieri V., Sharpe N., De Quattro V., Bella J. N., de Simone G., Walker J. F., Hahn R. T., Dahlof B., Effects of Once-Daily Angiotensin-Converting Enzyme Inhibition and Calcium Channel Blockade-Based Antihypertensive Treatment Regimens on Left Ventricular Hypertrophy and Diastolic Filling in Hypertension: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) Trial, 10.1161/hc3601.095927
  79. Godfraind Théophile, Calcium-channel modulators for cardiovascular disease, 10.1517/14728214.11.1.49
  80. Sever Peter S, Dahlöf Björn, Poulter Neil R, Wedel Hans, Beevers Gareth, Caulfield Mark, Collins Rory, Kjeldsen Sverre E, Kristinsson Arni, McInnes Gordon T, Mehlsen Jesper, Nieminen Markku, O'Brien Eoin, Östergren Jan, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial, 10.1016/s0140-6736(03)12948-0
  81. Wang J.-G., Li Y., Franklin S. S., Safar M., Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview, 10.1161/hypertensionaha.107.089763
  82. Sasaki Hidehisa, Saiki Atsuhito, Endo Kei, Ban Noriko, Yamaguchi Takashi, Kawana Hidetoshi, Nagayama Daizi, Ohhira Masahiro, Oyama Tomokazu, Miyashita Yoh, Shirai Kohji, Protective Effects of Efonidipine, a T- and L-Type Calcium Channel Blocker, on Renal Function and Arterial Stiffness in Type 2 Diabetic Patients with Hypertension and Nephropathy, 10.5551/jat.1628
  83. Ozawa Yuri, Hayashi Koichi, Nagahama Takahiko, Fujiwara Keiji, Wakino Shu, Saruta Takao, Renal Afferent and Efferent Arteriolar Dilation by Nilvadipine: Studies in the Isolated Perfused Hydronephrotic Kidney : , 10.1097/00005344-199902000-00010
  84. Hayashi K, Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment, 10.1016/s0895-7061(02)03147-3
  85. Lichtlen P.R., Rafflenbeul W., Hecker H., Jost S., Hugenholtz P.G., Deckers J.W., Retardation of angiographic progression of coronary artery disease by nifedipine, 10.1016/0140-6736(90)91121-p
  86. Zanchetti Alberto, Rosei Enrico Agabiti, Palù Cesare Dal, Leonetti Gastone, Magnani Bruno, Pessina Achille, The Verapamil in Hypertension and Atherosclerosis Study (VHAS) : Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness, 10.1097/00004872-199816110-00014
  87. Pitt B., Byington R. P., Furberg C. D., Hunninghake D. B., Mancini G. B. J., Miller M. E., Riley W., Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events, 10.1161/01.cir.102.13.1503
  88. Simon A., Gariepy J., Moyse D., Levenson J., Differential Effects of Nifedipine and Co-Amilozide on the Progression of Early Carotid Wall Changes, 10.1161/01.cir.103.24.2949
  89. Borhani Nemat O., Final Outcome Results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) : A Randomized Controlled Trial, 10.1001/jama.1996.03540100029024
  90. Bangalore Sripal, Kamalakkannan Gayathri, Parkar Sanobar, Messerli Franz H., Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis, 10.1016/j.amjmed.2006.08.033
  91. Chrysant S G, Lee J, Melino M, Karki S, Heyrman R, Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension, 10.1038/jhh.2010.5
  92. Chrysant Steven G., Melino Michael, Karki Sulekha, Lee James, Heyrman Reinilde, The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study, 10.1016/j.clinthera.2008.04.002
  93. Oparil S, Chrysant S G, Melino M, Lee J, Karki S, Heyrman R, Long-term efficacy of a combination of amlodipine and olmesartan medoxomil±hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial, 10.1038/jhh.2010.16
  94. Fogari Roberto, Malamani Gian, Corradi Luca, Mugellini Amedeo, Preti Paola, Zoppi Annalisa, Derosa Giuseppe, Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients, 10.1007/s12325-010-0002-0
  95. Calhoun D. A., Lacourciere Y., Chiang Y. T., Glazer R. D., Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide: A Randomized Clinical Trial, 10.1161/hypertensionaha.109.131300
  96. Oparil Suzanne, Melino Michael, Lee James, Fernandez Victor, Heyrman Reinilde, Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study, 10.1016/j.clinthera.2010.07.008
  97. Fogari, Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine, 10.2147/vhrm.s9404
  98. Elliott William J., Calhoun David A., DeLucca Paul T., Gazdick Lisa P., Kerns Dawn E., Zeldin Robert K., Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial, 10.1016/s0149-2918(01)80099-0
  99. Stanton T, Reid J L, Fixed dose combination therapy in the treatment of hypertension, 10.1038/sj.jhh.1001312
  100. Jamerson Kenneth, Weber Michael A., Bakris George L., Dahlöf Björn, Pitt Bertram, Shi Victor, Hester Allen, Gupte Jitendra, Gatlin Marjorie, Velazquez Eric J., Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients, 10.1056/nejmoa0806182
  101. Afanas’ev Iu I, Klin Med (Mosk), 90, 66 (2012)
  102. Efimova I, Klin Med (Mosk), 90, 36 (2012)
  103. Chalmers J., Arima H., Woodward M., Mancia G., Poulter N., Hirakawa Y., Zoungas S., Patel A., Williams B., Harrap S., Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial, 10.1161/hypertensionaha.113.02252
  104. Kim-Mitsuyama Shokei, Ogawa Hisao, Matsui Kunihiko, Jinnouchi Tomio, Jinnouchi Hideaki, Arakawa Kikuo, for the OSCAR Study Group, An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone, 10.1038/ki.2012.326
  105. Godfraind Théophile, Calcium Channel Blockers, ISBN:9783034895996, 10.1007/978-3-0348-7859-3
  106. Wald David S., Law Malcolm, Morris Joan K., Bestwick Jonathan P., Wald Nicholas J., Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials, 10.1016/j.amjmed.2008.09.038
  107. Law M R, Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials, 10.1136/bmj.326.7404.1427
  108. Bautista Leonelo E, Blood pressure-lowering effects of statins: who benefits? : , 10.1097/hjh.0b013e32832b1e78
  109. Martín-Ventura José L, Muñoz-Garcia Begoña, Blanco-Colio Luis M, Martín-Conejero Antonio, Madrigal-Matute Julio, Vega Melina, Ortega Luis, Serrano Javier, Egido Jesús, Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis, 10.1038/ki.2008.521
  110. Neutel Joel M., Bestermann William H., Dyess Eric M., Graff Alan, Kursun Attila, Sutradhar Santosh, Yunis Carla, The Use of a Single-Pill Calcium Channel Blocker/Statin Combination in the Management of Hypertension and Dyslipidemia: A Randomized, Placebo-Controlled, Multicenter Study, 10.1111/j.1751-7176.2008.00058.x
  111. Elliott H L, Meredith P A, Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the ‘ACTION’ database in patients with angina, 10.1038/jhh.2010.19
  112. Gorelick P. B., Scuteri A., Black S. E., DeCarli C., Greenberg S. M., Iadecola C., Launer L. J., Laurent S., Lopez O. L., Nyenhuis D., Petersen R. C., Schneider J. A., Tzourio C., Arnett D. K., Bennett D. A., Chui H. C., Higashida R. T., Lindquist R., Nilsson P. M., Roman G. C., Sellke F. W., Seshadri S., , Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association, 10.1161/str.0b013e3182299496
  113. Staessen Jan A, Fagard Robert, Thijs Lutgarde, Celis Hilde, Arabidze Guramy G, Birkenhäger Willem H, Bulpitt Christopher J, de Leeuw Peter W, Dollery Colin T, Fletcher Astrid E, Forette Françoise, Leonetti Gastone, Nachev Choudomir, O' Brien Eoin T, Rosenfeld Joseph, Rodicio José L, Tuomilehto Jaakko, Zanchetti Alberto, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension, 10.1016/s0140-6736(97)05381-6
  114. Forette Françoise, The Prevention of Dementia With Antihypertensive TreatmentNew Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study, 10.1001/archinte.162.18.2046
  115. Nimmrich V, Eckert A, Calcium channel blockers and dementia : Calcium channels in neurodegenerative disorders, 10.1111/bph.12240